Strand Life Sciences has developed an integrated version of ChemAxon's JChem suite of software with Admetis, a tool for modelling and predicting drug-relevant properties of molecules in silico. The integrated offering will be launched in Q1 2006.
According to the company release, Strand's Admetis gives users the power to build custom models using their own data. This is made possible through easy and intuitive model-building workflows based on expertise in silico model building. The software is packaged with its pre-built models, truPK and truTox, for predicting bioavailability, Protein binding, Volume distribution, elimination half-life, rate of absorption and hERG binding. It also has an extensive data mining and visualization module that supports an embedded chemical structure viewer.
The inclusion of ChemAxon's JChem toolkit provides Admetis with a feature rich, chemically aware data management and search framework. Its users will be able to undertake chemical editing and visualization and build complex queries using structural and non structural data.
According to Kas Subramanian, CSO, Strand Life Sciences, the product's pre-built models with a workflow-based modeling platform makes it distinct." We believe that the integration of JChem suite of software will benefit our customers."
"We are happy that we have such a good fit with the Admetis offering and given Strand's expertise and ambitious plans for future development we see a bright future for the collaboration," said Ferenc Csizmadia, CEO of ChemAxon.
ChemAxon is a leader in providing Java-based chemical software development platforms for the biotechnology and pharmaceutical industries. Its core capabilities include structure visualization and management, property prediction, virtual synthesis, screening and drug design. Further it creates powerful, cost effective cross platform solutions and programming interfaces to power modern cheminformatics and chemical communication.